Keywords: body composition, fat-free mass, glp-1 receptor agonists, lean mass, low testosterone, obesity pharmacotherapy, sarcopenia, skeletal muscle, testosterone replacement therapy Introduction and background Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as highly effective pharmacologic therapies for obesity and type 2 diabetes mellitus, producing substantial and sustained weight loss while improving cardiometabolic outcomes
And realistically, social media is only going to push that trend even further.
ATX-101 for reduction of submental fat: A phase III randomized controlled trial
Introduction Since its discovery by Posner (Figure 1)
Trends Neurosci 2008
doi: 10.2337/db21-0848 Summary Keywords GLP-1 - glucagon-like peptide-1, GIP - glucose-dependent insulinotropic peptide, obesity, incretin, pharmacology Citation Douros JD, Flak JN and Knerr PJ (2025) The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
